However, intermittent dosing of the PI3Kδ inhibitor in combination with anti-LAG-3 treatment prevented the initial development of irAE and enabled excellent tumor control without systemic adverse effects.<h4>Conclusions</h4>Our data demonstrated that refining immunotherapy delivery approaches can improve tolerability that ultimately transforms treatment success. Here, LAG3 is linked to neoplasm.